PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

This study has been completed.
Sponsor:
Collaborators:
GlaxoSmithKline
Bayer
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00153062
First received: September 9, 2005
Last updated: April 22, 2014
Last verified: April 2014
  Purpose

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.


Condition Intervention Phase
Stroke
Drug: Aggrenox
Drug: Clopidogrel placebo
Drug: Micardis
Drug: Aggrenox placebo
Drug: Clopidogrel
Drug: Micardis placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only) [ Time Frame: time since randomization; follow-up period is 1.5 to 4.4 years ]
  • Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only) [ Time Frame: time since randomization; follow-up period is 1.5 to 4.4 years ]

Secondary Outcome Measures:
  • Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only) [ Time Frame: time since randomization; follow-up period is 1.5 to 4.4 years ]
    Number of patients with any of stroke, myocardial infarction, vascular death

  • Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only) [ Time Frame: time since randomization; follow-up period is 1.5 to 4.4 years ]
    Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure

  • Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only) [ Time Frame: Randomization to final patient contact ]

Enrollment: 20332
Study Start Date: August 2003
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Aggrenox, Clopidogrel placebo, Micardis
Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis (80mg) qd
Drug: Aggrenox
25mg aspirin, 200 mg dipyridamole
Drug: Clopidogrel placebo
placebo
Drug: Micardis
80 mg micardis
Placebo Comparator: Aggrenox placebo, clopidogrel,, Micardis
Clopidogrel (75mg) qd; Aggrenox placebo bid, Micardis (80mg) qd
Drug: Micardis
80 mg micardis
Drug: Aggrenox placebo
placebo
Drug: Clopidogrel
75 mg clopidogrel
Placebo Comparator: Aggrenox, clop placebo, micardis placebo
Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis placebo qd
Drug: Aggrenox
25mg aspirin, 200 mg dipyridamole
Drug: Clopidogrel placebo
placebo
Drug: Micardis placebo
placebo
Placebo Comparator: Aggrenox plcebo, clop, micardis placebo
Clopidogrel (75mg) qd, Aggrenox placebo bid, Micardis placebo qd.
Drug: Aggrenox placebo
placebo
Drug: Clopidogrel
75 mg clopidogrel
Drug: Micardis placebo
placebo

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Male or female subjects 55 year or older who have suffered an ischemic stroke within the past 90 days and who meet all other inclusion criteria. Include also patients of ages 50 - 54 years and/or 90 to 120 days after the qualifying stroke provided the patient has at least two of the following additional risk factors:

  • Diabetes mellitus
  • Hypertension (systolic BP ¿ 140 or diastolic BP ¿ 90)
  • Smoker at time of qualifying stroke
  • Obesity (BMI>30; BMI=weight (kg)/[height (m)]2)
  • Previous vascular disease (stroke, MI, or peripheral arterial disease prior to qualifying stroke)
  • End-organ-damage (retinopathy, LVH, or microalbuminuria)
  • Hyperlipidemia

Exclusion criteria:

hemorrhagic stroke (must be ruled out by imaging);unable to give informed consent; known brain tumor, severe renal or hepatic insufficiency, current active peptic ulcer disease, severe coronary artery disease including unstable angina pectoris or an MI within the previous 3 months,or history of a hemostatic disorder or systemic bleeding ;hyperkalemia;uncorrected volume or sodium depletion; pre-stroke history of dementia;modified Rankin score greater than 4;qualifying stroke induced by surgical or cardiovascular procedure;uncontrolled hypertension at entry above 180/110 mmHg (goal BPs are lower); SBP 120 mmHg or less for hospitalized patients; currently taking an ARB and not able or willing to switch to alternative; required or planned continuing treatment with antithrombotics or anticoagulants including heparin or warfarin or non-study platelet inhibitors; syndrome of asthma, rhinitis and nasal polyps;scheduled for major surgery, carotid endarterectomy, or carotid angioplasty (4 weeks post surgery is allowed);unlikely to be released from hospital following the qualifying stroke or presence of a severe disability likely to lead to being bedridden or demented or a non-vascular disease or condition which makes it unlikely that the patient will survive to the end of the trial; history of thrombocytopenia or neutropenia.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00153062

  Hide Study Locations
Locations
United States, Alabama
9.159.1101 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
9.159.1173 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
9.159.1058 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
9.159.1087 Boehringer Ingelheim Investigational Site
Montgomery, Alabama, United States
9.159.1081 Boehringer Ingelheim Investigational Site
Northport, Alabama, United States
United States, Arizona
9.159.1149 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
9.159.1022 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
9.159.1133 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
9.159.1137 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
United States, Arkansas
9.159.1184 Boehringer Ingelheim Investigational Site
Fayetteville, Arkansas, United States
9.159.1005 Boehringer Ingelheim Investigational Site
Fort Smith, Arkansas, United States
9.159.1136 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas, United States
9.159.1062 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
United States, California
9.159.1040 Boehringer Ingelheim Investigational Site
Berkeley, California, United States
9.159.1180 Boehringer Ingelheim Investigational Site
Carmichael, California, United States
9.159.1114 Boehringer Ingelheim Investigational Site
Irvine, California, United States
9.159.1202 Boehringer Ingelheim Investigational Site
Laguna Hills, California, United States
9.159.1111 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
9.159.1100 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
9.159.1052 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
9.159.1165 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
9.159.1036 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
9.159.1134 Boehringer Ingelheim Investigational Site
Oceanside, California, United States
9.159.1002 Boehringer Ingelheim Investigational Site
Palo Alto, California, United States
9.159.1108 Boehringer Ingelheim Investigational Site
Redding, California, United States
9.159.1198 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
9.159.1013 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
9.159.1029 Boehringer Ingelheim Investigational Site
San Diego, California, United States
9.159.1185 Boehringer Ingelheim Investigational Site
San Francisco, California, United States
9.159.1218 Boehringer Ingelheim Investigational Site
San Jose, California, United States
9.159.1179 Boehringer Ingelheim Investigational Site
Santa Rosa, California, United States
9.159.1162 Boehringer Ingelheim Investigational Site
Sylmar, California, United States
9.159.1183 Boehringer Ingelheim Investigational Site
Torrance, California, United States
9.159.1205 Boehringer Ingelheim Investigational Site
Walnut Creek, California, United States
United States, Colorado
9.159.1118 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
9.159.1045 Boehringer Ingelheim Investigational Site
Englewood, Colorado, United States
United States, Connecticut
9.159.1038 Boehringer Ingelheim Investigational Site
Danbury, Connecticut, United States
9.159.1196 Boehringer Ingelheim Investigational Site
Fairfield, Connecticut, United States
9.159.1018 Boehringer Ingelheim Investigational Site
Hartford, Connecticut, United States
United States, Delaware
9.159.1080 Boehringer Ingelheim Investigational Site
Newark, Delaware, United States
United States, District of Columbia
9.159.1120 Boehringer Ingelheim Investigational Site
Washington, District of Columbia, United States
9.159.1216 Boehringer Ingelheim Investigational Site
Washington, District of Columbia, United States
United States, Florida
9.159.1057 Boehringer Ingelheim Investigational Site
Bay Pines, Florida, United States
9.159.1217 Boehringer Ingelheim Investigational Site
Boca Raton, Florida, United States
9.159.1096 Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States
9.159.1144 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
9.159.1007 Boehringer Ingelheim Investigational Site
Ft. Lauderdale, Florida, United States
9.159.1190 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
9.159.1150 Boehringer Ingelheim Investigational Site
Ocala, Florida, United States
9.159.1153 Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
9.159.1041 Boehringer Ingelheim Investigational Site
Plantation, Florida, United States
9.159.1072 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
9.159.1063 Boehringer Ingelheim Investigational Site
Sarasota, Florida, United States
9.159.1208 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
9.159.1049 Boehringer Ingelheim Investigational Site
Vero Beach, Florida, United States
9.159.1176 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida, United States
United States, Georgia
9.159.1071 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
9.159.1079 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
9.159.1181 Boehringer Ingelheim Investigational Site
Columbus, Georgia, United States
9.159.1138 Boehringer Ingelheim Investigational Site
Decatur, Georgia, United States
9.159.1070 Boehringer Ingelheim Investigational Site
Rome, Georgia, United States
9.159.1107 Boehringer Ingelheim Investigational Site
Savannah, Georgia, United States
United States, Idaho
9.159.1189 Boehringer Ingelheim Investigational Site
Boise, Idaho, United States
United States, Illinois
9.159.1060 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
9.159.1033 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
9.159.1026 University of Illinois
Chicago, Illinois, United States
9.159.1044 Boehringer Ingelheim Investigational Site
Maywood, Illinois, United States
9.159.1054 Boehringer Ingelheim Investigational Site
Palos Heights, Illinois, United States
9.159.1068 Boehringer Ingelheim Investigational Site
Park Ridge, Illinois, United States
9.159.1178 Boehringer Ingelheim Investigational Site
Peoria, Illinois, United States
United States, Indiana
9.159.1156 Boehringer Ingelheim Investigational Site
Elkhart, Indiana, United States
9.159.1092 Boehringer Ingelheim Investigational Site
South Bend, Indiana, United States
United States, Iowa
9.159.1027 Boehringer Ingelheim Investigational Site
Cedar Rapids, Iowa, United States
9.159.1187 Boehringer Ingelheim Investigational Site
Des Moines, Iowa, United States
9.159.1119 Boehringer Ingelheim Investigational Site
Des Moines, Iowa, United States
9.159.1059 Boehringer Ingelheim Investigational Site
Iowa City, Iowa, United States
9.159.1135 Boehringer Ingelheim Investigational Site
Waterloo, Iowa, United States
United States, Kansas
9.159.1090 Boehringer Ingelheim Investigational Site
Kansas City, Kansas, United States
United States, Kentucky
9.159.1129 Central Baptis Hospital
Lexington, Kentucky, United States
9.159.1206 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
9.159.1212 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
9.159.1131 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
9.159.1091 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
9.159.1147 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
United States, Louisiana
9.159.1106 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana, United States
9.159.1194 Boehringer Ingelheim Investigational Site
Marrero, Louisiana, United States
9.159.1083 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
9.159.1195 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana, United States
United States, Maryland
9.159.1055 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
9.159.1139 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
9.159.1024 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
United States, Massachusetts
9.159.1104 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
9.159.1031 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
9.159.1166 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
9.159.1066 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
9.159.1192 Boehringer Ingelheim Investigational Site
South Weymouth, Massachusetts, United States
9.159.1039 Boehringer Ingelheim Investigational Site
Worchester, Massachusetts, United States
United States, Michigan
9.159.1019 Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
9.159.1089 Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
9.159.1048 Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
9.159.1078 Boehringer Ingelheim Investigational Site
East Lansing, Michigan, United States
9.159.1143 Boehringer Ingelheim Investigational Site
Grand Rapids, Michigan, United States
9.159.1102 Boehringer Ingelheim Investigational Site
Kalamazoo, Michigan, United States
9.159.1011 Boehringer Ingelheim Investigational Site
Saginaw, Michigan, United States
9.159.1132 Boehringer Ingelheim Investigational Site
Southfield, Michigan, United States
United States, Minnesota
9.159.1158 Boehringer Ingelheim Investigational Site
Duluth, Minnesota, United States
9.159.1088 Boehringer Ingelheim Investigational Site
Duluth, Minnesota, United States
9.159.1084 Boehringer Ingelheim Investigational Site
Golden Valley, Minnesota, United States
9.159.1113 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
9.159.1097 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
United States, Missouri
9.159.1128 St. Luke's Hospital MABSI Research
Kansas City, Missouri, United States
9.159.1172 Boehringer Ingelheim Investigational Site
Lees Summit, Missouri, United States
9.159.1174 Boehringer Ingelheim Investigational Site
Saint Louis, Missouri, United States
9.159.1009 Boehringer Ingelheim Investigational Site
Springfield, Missouri, United States
9.159.1182 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
9.159.1191 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, Montana
9.159.1146 Boehringer Ingelheim Investigational Site
Great Falls, Montana, United States
United States, Nebraska
9.159.1201 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, Nevada
9.159.1127 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
9.159.1188 Boehringer Ingelheim Investigational Site
Reno, Nevada, United States
United States, New Jersey
9.159.1204 Boehringer Ingelheim Investigational Site
Camden, New Jersey, United States
9.159.1203 Boehringer Ingelheim Investigational Site
Edison, New Jersey, United States
9.159.1042 Neurology Consultants of Burlington County
Lumberton, New Jersey, United States
9.159.1209 Boehringer Ingelheim Investigational Site
New Brunswick, New Jersey, United States
9.159.1125 Boehringer Ingelheim Investigational Site
Newark, New Jersey, United States
9.159.1095 Boehringer Ingelheim Investigational Site
Ridgewood, New Jersey, United States
United States, New Mexico
9.159.1170 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
United States, New York
9.159.1086 Boehringer Ingelheim Investigational Site
Albany, New York, United States
9.159.1121 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
9.159.1130 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
9.159.1064 Boehringer Ingelheim Investigational Site
Brooklyn, New York, United States
9.159.1186 Boehringer Ingelheim Investigational Site
Brooklyn, New York, United States
9.159.1017 Boehringer Ingelheim Investigational Site
Brooklyn, New York, United States
9.159.1151 Boehringer Ingelheim Investigational Site
Buffalo, New York, United States
9.159.1076 North Shore University Hospital
Manasset, New York, United States
9.159.1037 Boehringer Ingelheim Investigational Site
Mineola, New York, United States
9.159.1220 Boehringer Ingelheim Investigational Site
New Hyde Park, New York, United States
9.159.1142 Saint Luke's-Roosevelt Hospital
New York, New York, United States
9.159.1001 Boehringer Ingelheim Investigational Site
New York, New York, United States
9.159.1116 Boehringer Ingelheim Investigational Site
New York, New York, United States
9.159.1126 Boehringer Ingelheim Investigational Site
Schenectady, New York, United States
9.159.1163 Boehringer Ingelheim Investigational Site
Stony Brook, New York, United States
9.159.1169 Boehringer Ingelheim Investigational Site
Tonawanda, New York, United States
9.159.1065 Boehringer Ingelheim Investigational Site
White Plains, New York, United States
United States, North Carolina
9.159.1099 Boehringer Ingelheim Investigational Site
Asheville, North Carolina, United States
9.159.1046 Boehringer Ingelheim Investigational Site
Chapel Hill, North Carolina, United States
9.159.1094 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
9.159.1012 Boehringer Ingelheim Investigational Site
High Point, North Carolina, United States
9.159.1115
Wilmington, North Carolina, United States
9.159.1110 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
9.159.1051 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
United States, North Dakota
9.159.1215 Boehringer Ingelheim Investigational Site
Bismarck, North Dakota, United States
9.159.1152 Boehringer Ingelheim Investigational Site
Fargo, North Dakota, United States
United States, Ohio
9.159.1159 Boehringer Ingelheim Investigational Site
Akron, Ohio, United States
9.159.1085 Boehringer Ingelheim Investigational Site
Canton, Ohio, United States
9.159.1032 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
9.159.1025 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
9.159.1177 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
9.159.1141 Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
9.159.1008 Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
9.159.1053 Boehringer Ingelheim Investigational Site
Toledo, Ohio, United States
9.159.1122 Boehringer Ingelheim Investigational Site
Youngstown, Ohio, United States
United States, Oklahoma
9.159.1199 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
United States, Oregon
9.159.1010 Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
United States, Pennsylvania
9.159.1171 Boehringer Ingelheim Investigational Site
Abington, Pennsylvania, United States
9.159.1214 Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania, United States
9.159.1210 Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania, United States
9.159.1200 Boehringer Ingelheim Investigational Site
Erie, Pennsylvania, United States
9.159.1043 Boehringer Ingelheim Investigational Site
Greensburg, Pennsylvania, United States
9.159.1164 Boehringer Ingelheim Investigational Site
Hershey, Pennsylvania, United States
9.159.1175 Boehringer Ingelheim Investigational Site
Lancaster, Pennsylvania, United States
9.159.1056 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
9.159.1074 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
9.159.1016 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
9.159.1112 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
9.159.1148 Boehringer Ingelheim Investigational Site
Upland, Pennsylvania, United States
United States, Rhode Island
9.159.1123 Boehringer Ingelheim Investigational Site
Providence, Rhode Island, United States
United States, South Carolina
9.159.1140 Boehringer Ingelheim Investigational Site
Columbia, South Carolina, United States
9.159.1207 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
9.159.1004 Boehringer Ingelheim Investigational Site
Spartanberg, South Carolina, United States
United States, Tennessee
9.159.1006 Boehringer Ingelheim Investigational Site
Bristol, Tennessee, United States
9.159.1154 Boehringer Ingelheim Investigational Site
Knoxville, Tennessee, United States
9.159.1213 Boehringer Ingelheim Investigational Site
Memphis, Tennessee, United States
9.159.1075 Boehringer Ingelheim Investigational Site
Nashville, Tennessee, United States
United States, Texas
9.159.1219 Boehringer Ingelheim Investigational Site
Brownwood, Texas, United States
9.159.1197 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
9.159.1155 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
9.159.1082 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
9.159.1160 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
9.159.1023 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
9.159.1020 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
9.159.1047 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
9.159.1069 Boehringer Ingelheim Investigational Site
Tyler, Texas, United States
United States, Utah
9.159.1003 Boehringer Ingelheim Investigational Site
Bountiful, Utah, United States
United States, Virginia
9.159.1077 Boehringer Ingelheim Investigational Site
Newport News, Virginia, United States
9.159.1021 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
9.159.1061 Boehringer Ingelheim Investigational Site
Salem, Virginia, United States
United States, Washington
9.159.1014 Boehringer Ingelheim Investigational Site
Seattle, Washington, United States
9.159.1145 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
United States, West Virginia
9.159.1211 Boehringer Ingelheim Investigational Site
Charleston, West Virginia, United States
9.159.1035 Boehringer Ingelheim Investigational Site
Morgantown, West Virginia, United States
United States, Wisconsin
9.159.1030 Boehringer Ingelheim Investigational Site
Marshfield, Wisconsin, United States
9.159.1117 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
9.159.1098 Community Healthcare Clinic Westhill Medical Specialists
Wausau, Wisconsin, United States
Argentina
9.159.1331 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
9.159.1333 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
9.159.1334 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
9.159.1335 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
9.159.1336 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
9.159.1332 Boehringer Ingelheim Investigational Site
Rosario, Sta. Fe, Argentina
9.159.1342 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
Australia, New South Wales
9.159.2444 Boehringer Ingelheim Investigational Site
Gosford, New South Wales, Australia
9.159.2449 Boehringer Ingelheim Investigational Site
New Lambton, New South Wales, Australia
9.159.2448 Boehringer Ingelheim Investigational Site
Westmead, New South Wales, Australia
Australia, Queensland
9.159.2450 Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
9.159.2452 Boehringer Ingelheim Investigational Site
Southport, Queensland, Australia
Australia, South Australia
9.159.2451 Boehringer Ingelheim Investigational Site
Bedford Park, South Australia, Australia
Australia, Victoria
9.159.2443 Boehringer Ingelheim Investigational Site
Box Hill, Victoria, Australia
9.159.2447 Boehringer Ingelheim Investigational Site
Melbourne, Victoria, Australia
9.159.2445 Boehringer Ingelheim Investigational Site
Parkville, Victoria, Australia
9.159.2446 Boehringer Ingelheim Investigational Site
West Heidelberg, Victoria, Australia
Austria
9.159.1515 Boehringer Ingelheim Investigational Site
Graz, Austria
9.159.1519 Boehringer Ingelheim Investigational Site
Graz, Austria
9.159.1517 Boehringer Ingelheim Investigational Site
Innsbruck, Austria
9.159.1516 Boehringer Ingelheim Investigational Site
Linz, Austria
9.159.1518 Boehringer Ingelheim Investigational Site
Ma.Gugging/Klosterneuburg, Austria
9.159.1520 Boehringer Ingelheim Investigational Site
St. Pölten, Austria
9.159.1521 Boehringer Ingelheim Investigational Site
Wien, Austria
Belgium
9.159.1553 Boehringer Ingelheim Investigational Site
Aalst, Belgium
9.159.1543 Boehringer Ingelheim Investigational Site
Anderlecht, Belgium
9.159.1552 Boehringer Ingelheim Investigational Site
Antwerpen, Belgium
9.159.1546 Boehringer Ingelheim Investigational Site
Bonheiden, Belgium
9.159.1547 Boehringer Ingelheim Investigational Site
Brugge, Belgium
9.159.1550 Boehringer Ingelheim Investigational Site
Bruxelles, Belgium
9.159.1549 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
9.159.1555 Boehringer Ingelheim Investigational Site
Kortrijk, Belgium
9.159.1554 Boehringer Ingelheim Investigational Site
La Louvière, Belgium
9.159.1544 Boehringer Ingelheim Investigational Site
Leuven, Belgium
9.159.1548 Boehringer Ingelheim Investigational Site
Montegnée, Belgium
9.159.1556 Boehringer Ingelheim Investigational Site
Ottignies, Belgium
9.159.1545 Boehringer Ingelheim Investigational Site
Wilrijk, Belgium
9.159.1551 Boehringer Ingelheim Investigational Site
Yvoir, Belgium
Brazil
9.159.2869 Complexo Hospitalar Universitario Prof Edgard Santos
Salvador, Brazil
9.159.2853 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
Canada, Alberta
9.159.1397 Foothills Medical Centre
Calgary, Alberta, Canada
9.159.1382 Boehringer Ingelheim Investigational Site
Edmonton, Alberta, Canada
9.159.1390 Boehringer Ingelheim Investigational Site
Lethbridge, Alberta, Canada
Canada, British Columbia
9.159.1370 Boehringer Ingelheim Investigational Site
Kamloops, British Columbia, Canada
9.159.1368 Boehringer Ingelheim Investigational Site
New Westminster, British Columbia, Canada
9.159.1376 Boehringer Ingelheim Investigational Site
Penticton, British Columbia, Canada
9.159.1387 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
9.159.1377 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
Canada, Manitoba
9.159.1394 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba, Canada
9.159.1355 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba, Canada
Canada, New Brunswick
9.159.1356 Boehringer Ingelheim Investigational Site
Saint John, New Brunswick, Canada
Canada, Newfoundland and Labrador
9.159.1392 Boehringer Ingelheim Investigational Site
Corner Brook, Newfoundland and Labrador, Canada
9.159.1385 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador, Canada
Canada, Nova Scotia
9.159.1373 Boehringer Ingelheim Investigational Site
Sydney, Nova Scotia, Canada
Canada, Ontario
9.159.1393 Boehringer Ingelheim Investigational Site
Barrie, Ontario, Canada
9.159.1395 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
9.159.1360 Boehringer Ingelheim Investigational Site
Kingston, Ontario, Canada
9.159.1367 Boehringer Ingelheim Investigational Site
London, Ontario, Canada
9.159.1384 Boehringer Ingelheim Investigational Site
London, Ontario, Canada
9.159.1380 Boehringer Ingelheim Investigational Site
Mississauga, Ontario, Canada
9.159.1378 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
9.159.1381 Ottawa Hospital General Campus
Ottawa, Ontario, Canada
9.159.1366 Boehringer Ingelheim Investigational Site
Richmond Hill, Ontario, Canada
9.159.1365 Boehringer Ingelheim Investigational Site
Scarborough, Ontario, Canada
9.159.1375 Boehringer Ingelheim Investigational Site
Scarborough, Ontario, Canada
9.159.1391 Boehringer Ingelheim Investigational Site
Tecumseh, Ontario, Canada
9.159.1369 Boehringer Ingelheim Investigational Site
Thunder Bay, Ontario, Canada
9.159.1379 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
9.159.1383 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
9.159.1357 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
9.159.1363 Boehringer Ingelheim Investigational Site
Windsor, Ontario, Canada
Canada, Quebec
9.159.1359 Boehringer Ingelheim Investigational Site
Greenfield Park, Quebec, Canada
9.159.1374 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
9.159.1361 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
9.159.1362 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
9.159.1371 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
9.159.1388 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
9.159.1372 Boehringer Ingelheim Investigational Site
Quebec City, Quebec, Canada
9.159.1358 Boehringer Ingelheim Investigational Site
Saguenay, Quebec, Canada
9.159.1364 Boehringer Ingelheim Investigational Site
St. Jerome, Quebec, Canada
Canada, Saskatchewan
9.159.1389 Boehringer Ingelheim Investigational Site
Regina, Saskatchewan, Canada
9.159.1396 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
China
9.159.2496 Boehringer Ingelheim Investigational Site
Beijing, China
9.159.2490 Boehringer Ingelheim Investigational Site
Beijing, China
9.159.2491 Boehringer Ingelheim Investigational Site
Beijing, China
9.159.2492 Boehringer Ingelheim Investigational Site
Beijing, China
9.159.2494 Boehringer Ingelheim Investigational Site
Beijing, China
9.159.2495 Boehringer Ingelheim Investigational Site
Beijing, China
9.159.2493 Boehringer Ingelheim Investigational Site
Beijing, China
9.159.2503 Boehringer Ingelheim Investigational Site
Changchun, Jilin Province, China
9.159.2500 Boehringer Ingelheim Investigational Site
Changsha, Hunan Province, China
9.159.2513 Boehringer Ingelheim Investigational Site
Chengdu, Sichuan Province, China
9.159.2512 Boehringer Ingelheim Investigational Site
Chongqing, China
9.159.2518 Boehringer Ingelheim Investigational Site
Guangzhou, China
9.159.2521 Boehringer Ingelheim Investigational Site
Guangzhou, China
9.159.2509 Boehringer Ingelheim Investigational Site
Guangzhou, China
9.159.2510 Boehringer Ingelheim Investigational Site
Guangzhou, Guangdong Province, China
9.159.2507 Boehringer Ingelheim Investigational Site
Guangzhou, Guangdong Province, China
9.159.2502 Boehringer Ingelheim Investigational Site
Hangzhou, Zhejiang Province, China
9.159.2504 Boehringer Ingelheim Investigational Site
Harbin, Heilongjiang Province, China
9.159.2505 Boehringer Ingelheim Investigational Site
Jinan, Shandong Province, China
9.159.2506 Boehringer Ingelheim Investigational Site
Jinan, Shangdong Province, China
9.159.2517 Boehringer Ingelheim Investigational Site
Nanjing, Jiangsu Province, China
9.159.2519 Boehringer Ingelheim Investigational Site
Nanjing, Jiangsu Province, China
9.159.2520 Boehringer Ingelheim Investigational Site
Nanjing, Jiangsu Province, China
9.159.2484 Boehringer Ingelheim Investigational Site
Shanghai, China
9.159.2483 Boehringer Ingelheim Investigational Site
Shanghai, China
9.159.2489 Boehringer Ingelheim Investigational Site
Shanghai, China
9.159.2488 Boehringer Ingelheim Investigational Site
Shanghai, China
9.159.2487 Boehringer Ingelheim Investigational Site
Shanghai, China
9.159.2486 Boehringer Ingelheim Investigational Site
Shanghai, China
9.159.2485 Boehringer Ingelheim Investigational Site
Shanghai, China
9.159.2516 Boehringer Ingelheim Investigational Site
Suzhou, Jiangsu Province, China
9.159.2497 Boehringer Ingelheim Investigational Site
Tianjin, China
9.159.2501 Boehringer Ingelheim Investigational Site
Wenzhou, Zhejiang Province, China
9.159.2499 Boehringer Ingelheim Investigational Site
Wuhan, Hubei Province, China
9.159.2498 Boehringer Ingelheim Investigational Site
Wuhan, Hubei Province, China
9.159.2511 Boehringer Ingelheim Investigational Site
Xian, China
9.159.2514 Boehringer Ingelheim Investigational Site
Xian, Shanxi, China
9.159.2515 Boehringer Ingelheim Investigational Site
Xian, Shanxi Province, China
Denmark
9.159.1636 Boehringer Ingelheim Investigational Site
Aarhuc C, Denmark
9.159.1635 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
9.159.1639 Boehringer Ingelheim Investigational Site
Esbjerg, Denmark
9.159.1634 Boehringer Ingelheim Investigational Site
Frederiksberg, Denmark
9.159.1637 Boehringer Ingelheim Investigational Site
Glostrup, Denmark
9.159.1640 Boehringer Ingelheim Investigational Site
Hellerup, Denmark
9.159.1638 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
9.159.1633 Boehringer Ingelheim Investigational Site
København NV, Denmark
9.159.1631 Boehringer Ingelheim Investigational Site
København Ø, Denmark
9.159.1632 Boehringer Ingelheim Investigational Site
Odense, Denmark
El Salvador
9.159.2181 Boehringer Ingelheim Investigational Site
Oviedo, El Salvador
Finland
9.159.1655 Boehringer Ingelheim Investigational Site
Helsinki, Finland
9.159.1658 Boehringer Ingelheim Investigational Site
Kuopio, Finland
9.159.1659 Boehringer Ingelheim Investigational Site
Lappeenranta, Finland
9.159.1656 Boehringer Ingelheim Investigational Site
Oulu, Finland
9.159.1657 Boehringer Ingelheim Investigational Site
Seinäjoki, Finland
France
9.159.1680 Boehringer Ingelheim Investigational Site
Lille cedex, France
9.159.1683 Boehringer Ingelheim Investigational Site
Limoges cedex 1, France
9.159.1681 Boehringer Ingelheim Investigational Site
Marseille cedex 05, France
9.159.1679 Boehringer Ingelheim Investigational Site
Nancy, France
9.159.1685 Boehringer Ingelheim Investigational Site
Paris cedex 19, France
9.159.1682 Boehringer Ingelheim Investigational Site
Poitiers cedex, France
9.159.1684 Boehringer Ingelheim Investigational Site
Tours cedex 9, France
Germany
9.159.1713 Boehringer Ingelheim Investigational Site
Bad Neustadt/Saale, Germany
9.159.1736 Boehringer Ingelheim Investigational Site
Berlin, Germany
9.159.1732 Boehringer Ingelheim Investigational Site
Braunschweig, Germany
9.159.1726 Boehringer Ingelheim Investigational Site
Cloppenburg, Germany
9.159.1723 Boehringer Ingelheim Investigational Site
Dresden, Germany
9.159.1728 Boehringer Ingelheim Investigational Site
Düsseldorf, Germany
9.159.1707 Boehringer Ingelheim Investigational Site
Essen, Germany
9.159.1738 Boehringer Ingelheim Investigational Site
Freiburg, Germany
9.159.1720 Boehringer Ingelheim Investigational Site
Gießen, Germany
9.159.1739 Boehringer Ingelheim Investigational Site
Hamburg, Germany
9.159.1722 Boehringer Ingelheim Investigational Site
Hamburg, Germany
9.159.1724 Boehringer Ingelheim Investigational Site
Heidelberg, Germany
9.159.1734 Boehringer Ingelheim Investigational Site
Jena, Germany
9.159.1730 Boehringer Ingelheim Investigational Site
Kaiserslautern, Germany
9.159.1737 Boehringer Ingelheim Investigational Site
Köln, Germany
9.159.1717 Boehringer Ingelheim Investigational Site
Leipzig, Germany
9.159.1735 Boehringer Ingelheim Investigational Site
Ludwigshafen am Rhein, Germany
9.159.1712 Boehringer Ingelheim Investigational Site
Magdeburg, Germany
9.159.1710 Boehringer Ingelheim Investigational Site
Mainz, Germany
9.159.1709 Boehringer Ingelheim Investigational Site
Minden, Germany
9.159.1716 Boehringer Ingelheim Investigational Site
Mönchengladbach, Germany
9.159.1725 Boehringer Ingelheim Investigational Site
München, Germany
9.159.1718 Boehringer Ingelheim Investigational Site
München, Germany
9.159.1729 Boehringer Ingelheim Investigational Site
München, Germany
9.159.1727 Boehringer Ingelheim Investigational Site
Münster, Germany
9.159.1711 Boehringer Ingelheim Investigational Site
Nürnberg, Germany
9.159.1719 Boehringer Ingelheim Investigational Site
Regensburg, Germany
9.159.1731 Boehringer Ingelheim Investigational Site
Remscheid, Germany
9.159.1708 Boehringer Ingelheim Investigational Site
Rostock, Germany
9.159.1715 Boehringer Ingelheim Investigational Site
Saarbrücken, Germany
9.159.1714 Boehringer Ingelheim Investigational Site
Siegen, Germany
9.159.1733 Boehringer Ingelheim Investigational Site
Stuttgart, Germany
9.159.1721 Boehringer Ingelheim Investigational Site
Weimar, Germany
Greece
9.159.1826 Boehringer Ingelheim Investigational Site
Alexandroupolis, Greece
9.159.1819 Boehringer Ingelheim Investigational Site
Athens, Greece
9.159.1821 Boehringer Ingelheim Investigational Site
Athens, Greece
9.159.1820 Boehringer Ingelheim Investigational Site
Athens, Greece
9.159.1825 Boehringer Ingelheim Investigational Site
Ioannina, Greece
9.159.1824 Boehringer Ingelheim Investigational Site
Patras, Greece
Hong Kong
9.159.2713 Boehringer Ingelheim Investigational Site
Hong KoNG, Hong Kong
9.159.2714 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
India
9.159.2605 Boehringer Ingelheim Investigational Site
Annamalainagar, India
9.159.2620 Boehringer Ingelheim Investigational Site
Bangalore, India
9.159.2603 Boehringer Ingelheim Investigational Site
Bangalore, India
9.159.2616 Boehringer Ingelheim Investigational Site
Bikaner, India
9.159.2618 Boehringer Ingelheim Investigational Site
Calicut, India
9.159.2604 Boehringer Ingelheim Investigational Site
Chennai, India
9.159.2619 Boehringer Ingelheim Investigational Site
Chennai, India
9.159.2625 Boehringer Ingelheim Investigational Site
Chennai, India
9.159.2606 Boehringer Ingelheim Investigational Site
Cochin, India
9.159.2607 Boehringer Ingelheim Investigational Site
Hyderabad, India
9.159.2632 Boehringer Ingelheim Investigational Site
Hyderabad, India
9.159.2624 Boehringer Ingelheim Investigational Site
Hyderabad, India
9.159.2630 Boehringer Ingelheim Investigational Site
Hyderabad, India
9.159.2610 Boehringer Ingelheim Investigational Site
Indore, India
9.159.2617 Boehringer Ingelheim Investigational Site
Jaipur, India
9.159.2615 Boehringer Ingelheim Investigational Site
Jaipur, India
9.159.2612 Boehringer Ingelheim Investigational Site
Jodhpur, India
9.159.2621 Boehringer Ingelheim Investigational Site
Kottayam, India
9.159.2613 Boehringer Ingelheim Investigational Site
Lucknow, India
9.159.2614 Boehringer Ingelheim Investigational Site
Ludhiana, India
9.159.2611 Boehringer Ingelheim Investigational Site
Mumbai, India
9.159.2628 Boehringer Ingelheim Investigational Site
New Delhi, India
9.159.2629 Boehringer Ingelheim Investigational Site
New Delhi, India
9.159.2623 Boehringer Ingelheim Investigational Site
Patiala, India
9.159.2609 Boehringer Ingelheim Investigational Site
Pune, India
9.159.2622 Boehringer Ingelheim Investigational Site
Pune, India
9.159.2627 Boehringer Ingelheim Investigational Site
Secunderabad, India
9.159.2626 Boehringer Ingelheim Investigational Site
Trichy, India
9.159.2631 Boehringer Ingelheim Investigational Site
Visakhapatnam, India
9.159.2608 Boehringer Ingelheim Investigational Site
Wardha, India
Ireland
9.159.1851 Boehringer Ingelheim Investigational Site
Cork, Ireland
9.159.1852 Boehringer Ingelheim Investigational Site
Dublin 7, Ireland
Israel
9.159.2729 Barzilai Medical Center
Ashkelon, Israel
9.159.2721 Neurology Unit
Haifa, Israel
9.159.2724 Rambam Medical Center, Tel-Aviv Medical
Haifa, Israel
9.159.2723 Boehringer Ingelheim Investigational Site
Israel, Israel
9.159.2727 Western Galilee Hospital
Naharia, Israel
9.159.2722 Neurology Unit
Petach Tikva, Israel
9.159.2726 Sheba Medical Center
Tel Hashomer, Israel
9.159.2725 Tel Aviv Medical Center
Tel-Aviv, Israel
Italy
9.159.1875 Università degli Studi di Ancona
Ancona, Italy
9.159.1882 Ospedale Brotzu
Cagliari, Italy
9.159.1883 Azienda Ospedaliera S. Anna
Como, Italy
9.159.1871 Azienda Ospedaliera "Careggi"
Firenze, Italy
9.159.1869 Università degli Studi di Genova
Genova, Italy
9.159.1870 ASL No. 5 di Jesi
Jesi (ancona), Italy
9.159.1865 Ospedale Regionale "S. Salvatore"
L'aquila, Italy
9.159.1866 Ospedale S. Raffaele
Milano, Italy
9.159.1884 Ospedale S. Carlo Borromeo"
Milano, Italy
9.159.1873 Istituto Scientifico "S. Luca"
Milano, Italy
9.159.1868 Ospedale "S. Maria di Loreto Mare"
Napoli, Italy
9.159.1876 Azienda Ospedaliera di Padova -Policlinico Universitario
Padova, Italy
9.159.1874 Ospedale Civico - ARNAS
Palermo, Italy
9.159.1872 Neuromed IRCCS
Pozzilli (IS), Italy
9.159.1879 Policlinico S. Andrea
Roma, Italy
9.159.1881 Università "La Sapienza"
Roma, Italy
9.159.1877 Azienda Ospedaliera Umberto I
Siracusa, Italy
9.159.1878 Azienda Ospedaliera "Santo Maria"
Terni, Italy
9.159.1864 Azienda Ospedaliera "S. Giovanni Battista"
Torino, Italy
9.159.1863 Ospedale di Cattinara
Trieste, Italy
9.159.1867 Presidio Ospedaliero G.Jazzolino
Vibo Valentia, Italy
9.159.1880 Ospedale Civile
Vicenza, Italy
Japan
9.159.2964 Boehringer Ingelheim Investigational Site
Adachi-ku, Tokyo, Japan
9.159.2958 Boehringer Ingelheim Investigational Site
Akashi, Hyogo, Japan
9.159.2970 Boehringer Ingelheim Investigational Site
Akashi, Hyogo, Japan
9.159.2965 Boehringer Ingelheim Investigational Site
Ako, Hyogo, Japan
9.159.2968 Boehringer Ingelheim Investigational Site
Aoba-ku, Yokohama, Kanagawa, Japan
9.159.2951 Boehringer Ingelheim Investigational Site
Azumino, Nagano, Japan
9.159.2959 Boehringer Ingelheim Investigational Site
Chitose, Hokkaido, Japan
9.159.2944 Boehringer Ingelheim Investigational Site
Chuo-ku, Kobe, Hyogo, Japan
9.159.2947 Boehringer Ingelheim Investigational Site
Chuo-Ku, Sapporo, Hokkaido, Japan
9.159.2954 Boehringer Ingelheim Investigational Site
Fushimi-ku, Kyoto, Kyoto, Japan
9.159.2942 Boehringer Ingelheim Investigational Site
Habikino, Osaka, Japan
9.159.2948 Boehringer Ingelheim Investigational Site
Higashi-ku, Sapporo, Hokkaido, Japan
9.159.2957 Boehringer Ingelheim Investigational Site
Higashi-osaka, Osaka, Japan
9.159.2940 Boehringer Ingelheim Investigational Site
Higashinari-ku, Osaka, Osaka, Japan
9.159.2973 Boehringer Ingelheim Investigational Site
Higashiyodogawa-ku, Osaka, Osaka, Japan
9.159.2949 Boehringer Ingelheim Investigational Site
Hitachinaka, Ibaraki, Japan
9.159.2953 Boehringer Ingelheim Investigational Site
Iida, Nagano, Japan
9.159.2943 Boehringer Ingelheim Investigational Site
Izumisano, Osaka, Japan
9.159.2963 Boehringer Ingelheim Investigational Site
Jyonan-ku, Fukuoka, Fukuoka, Japan
9.159.2933 Boehringer Ingelheim Investigational Site
Kasama, Ibaraki, Japan
9.159.2955 Boehringer Ingelheim Investigational Site
Kasuga, Fukuoka, Japan
9.159.2938 Boehringer Ingelheim Investigational Site
Kita-ku, Osaka, Osaka, Japan
9.159.2967 Boehringer Ingelheim Investigational Site
Koriyama, Fukushima, Japan
9.159.2969 Boehringer Ingelheim Investigational Site
Kushiro, Hokkaido, Japan
9.159.2952 Boehringer Ingelheim Investigational Site
Matsumoto, Nagano, Japan
9.159.2961 Boehringer Ingelheim Investigational Site
Midori-ku, Yokohama, Kanagawa, Japan
9.159.2934 Boehringer Ingelheim Investigational Site
Moriya, Ibaraki, Japan
9.159.2971 Boehringer Ingelheim Investigational Site
Musashino, Tokyo, Japan
9.159.2962 Boehringer Ingelheim Investigational Site
Nakagawa-ku, Nagoya, Aichi, Japan
9.159.2939 Boehringer Ingelheim Investigational Site
Nishi-yodogawa-ku, Osaka, Osaka, Japan
9.159.2956 Boehringer Ingelheim Investigational Site
Ohnojo, Fukuoka, Japan
9.159.2941 Boehringer Ingelheim Investigational Site
Sakai-ku, Sakai, Osaka, Japan
9.159.2945 Boehringer Ingelheim Investigational Site
Sawara-ku, Fukuoka, Fukuoka, Japan
9.159.2937 Boehringer Ingelheim Investigational Site
Shimogyo-ku, Kyoto, Kyoto, Japan
9.159.2966 Boehringer Ingelheim Investigational Site
Shiroishi, Miyagi, Japan
9.159.2936 Boehringer Ingelheim Investigational Site
Suwa, Nagano, Japan
9.159.2946 Boehringer Ingelheim Investigational Site
Takikawa, Hokkaido, Japan
9.159.2935 Boehringer Ingelheim Investigational Site
Tatebayashi, Gunma, Japan
9.159.2950 Boehringer Ingelheim Investigational Site
Tsuchiura, Ibaraki, Japan
9.159.2972 Boehringer Ingelheim Investigational Site
Yao, Osaka, Japan
Korea, Republic of
9.159.1593 Boehringer Ingelheim Investigational Site
Gwangju, Korea, Republic of
9.159.1595 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
9.159.1592 Boehringer Ingelheim Investigational Site
Kyunggi-do, Korea, Republic of
9.159.1597 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
9.159.1591 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
9.159.1594 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
9.159.1596 Boehringer Ingelheim Investigational Site
Suwon, Korea, Republic of
Malaysia
9.159.2707 Boehringer Ingelheim Investigational Site
Kelantan Darul Naim, Malaysia
9.159.2706 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
Mexico
9.159.2765 Boehringer Ingelheim Investigational Site
Metepec, Mexico
Netherlands
9.159.1960 Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
9.159.1945 Medisch Centrum Alkmaar
Alkmaar, Netherlands
9.159.1963 Polikliniek Neurologie
Assen, Netherlands
9.159.1949 Ziekenhuis Gooi-Noord
Blaricum, Netherlands
9.159.1962 Locatie Molengracht
Breda, Netherlands
9.159.1950 HagaZiekenhuis
Den Haag, Netherlands
9.159.1959 Catharina Ziekenhuis
Eindhoven, Netherlands
9.159.1946 Scheper Ziekenhuis
Emmen, Netherlands
9.159.1958 Medisch Spectrum Twente
Enschede, Netherlands
9.159.1961 Lokatie Van Swieten
Groningen, Netherlands
9.159.1943 Umcg
Groningen, Netherlands
9.159.1953 Atrium Medisch Centrum
Heerlen, Netherlands
9.159.1955 Elkerliek Ziekenhuis
Helmond, Netherlands
9.159.1951 Ziekenhuisgroep Twente
Hengelo, Netherlands
9.159.1948 Medisch Centrum Leeuwarden
Leeuwarden, Netherlands
9.159.1952 Rijnland Ziekenhuis
Leiderdorp, Netherlands
9.159.1947 Sint Antonius Ziekenhuis
Nieuwegein, Netherlands
9.159.1964 Canisius-Wilhelmina ziekenhuis
Nijmegen, Netherlands
9.159.1957 Sint Elisabeth Ziekenhuis
Tilburg, Netherlands
9.159.1956 TweeSteden Ziekenhuis Tilburg
Tilburg, Netherlands
9.159.1944 Máxima Medisch Centrum
Veldhoven, Netherlands
9.159.1954 St. Jans Gasthuis
Weert, Netherlands
Norway
9.159.2029 Boehringer Ingelheim Investigational Site
Bergen, Norway
9.159.2028 Boehringer Ingelheim Investigational Site
Oslo, Norway
9.159.2027 Boehringer Ingelheim Investigational Site
Trondheim, Norway
Portugal
9.159.2040 Hospital Fernando Fonseca
Amadora, Portugal
9.159.2039 Centro Hospitalar e Universitário de Coimbra, EPE
Coimbra, Portugal
9.159.2041 Centro Hospitalar de Lisboa Norte
Lisboa, Portugal
9.159.2042 Centro Hospitalar do Porto
Porto, Portugal
Russian Federation
9.159.2114 Boehringer Ingelheim Investigational Site
Ekaterinburg, Russian Federation
9.159.2102 Boehringer Ingelheim Investigational Site
Kazan, Russian Federation
9.159.2117 Boehringer Ingelheim Investigational Site
Kemerovo, Russian Federation
9.159.2107 Boehringer Ingelheim Investigational Site
Kirov, Russian Federation
9.159.2116 Boehringer Ingelheim Investigational Site
Krasnoyarsk, Russian Federation
9.159.2087 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2081 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2080 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2093 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2083 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2084 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2085 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2095 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2092 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2101 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2089 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2090 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2091 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2098 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2082 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2088 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2079 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
9.159.2105 Boehringer Ingelheim Investigational Site
Nizhnyi Novgorod, Russian Federation
9.159.2115 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
9.159.2119 Boehringer Ingelheim Investigational Site
Omsk, Russian Federation
9.159.2111 Boehringer Ingelheim Investigational Site
Orel, Russian Federation
9.159.2106 Boehringer Ingelheim Investigational Site
Rostov-na-Donu, Russian Federation
9.159.2108 Boehringer Ingelheim Investigational Site
Samara, Russian Federation
9.159.2110 Boehringer Ingelheim Investigational Site
Saratov, Russian Federation
9.159.2109 Boehringer Ingelheim Investigational Site
Saratov, Russian Federation
9.159.2118 Boehringer Ingelheim Investigational Site
Seversk, Russian Federation
9.159.2086 Boehringer Ingelheim Investigational Site
Smolensk, Russian Federation
9.159.2094 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
9.159.2099 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
9.159.2097 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
9.159.2100 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
9.159.2120 Boehringer Ingelheim Investigational Site
Ufa, Russian Federation
9.159.2113 Boehringer Ingelheim Investigational Site
Volgograd, Russian Federation
9.159.2112 Boehringer Ingelheim Investigational Site
Volgograd, Russian Federation
9.159.2104 Boehringer Ingelheim Investigational Site
Voronezh, Russian Federation
9.159.2103 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
Singapore
9.159.2704 Boehringer Ingelheim Investigational Site
Singapore, Singapore
9.159.2705 Boehringer Ingelheim Investigational Site
Singapore, Singapore
9.159.2703 Boehringer Ingelheim Investigational Site
Singapore, Singapore
South Africa
9.159.2060 Boehringer Ingelheim Investigational Site
Bloemfontein, South Africa
9.159.2056 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
9.159.2057 Boehringer Ingelheim Investigational Site
Durban, South Africa
9.159.2061 Boehringer Ingelheim Investigational Site
Johannesburg, South Africa
9.159.2055 Boehringer Ingelheim Investigational Site
Johannesburg, South Africa
9.159.2058 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
9.159.2059 Boehringer Ingelheim Investigational Site
Sunninghill, South Africa
Spain
9.159.2179 Boehringer Ingelheim Investigational Site
Alicante, Spain
9.159.2177 Boehringer Ingelheim Investigational Site
Barcelona, Spain
9.159.2178 Boehringer Ingelheim Investigational Site
Hospitalet de Llobregat (Barcelona), Spain
9.159.2176 Boehringer Ingelheim Investigational Site
Madrid, Spain
9.159.2175 Boehringer Ingelheim Investigational Site
Madrid, Spain
9.159.2180 Boehringer Ingelheim Investigational Site
Pamplona, Spain
Sweden
9.159.2223 Boehringer Ingelheim Investigational Site
Borås, Sweden
9.159.2209 Boehringer Ingelheim Investigational Site
Eskilstuna, Sweden
9.159.2204 Boehringer Ingelheim Investigational Site
Göteborg, Sweden
9.159.2205 Boehringer Ingelheim Investigational Site
Göteborg, Sweden
9.159.2728 Neurology Unit
Holon, Sweden
9.159.2210 Boehringer Ingelheim Investigational Site
Jönköping, Sweden
9.159.2206 Boehringer Ingelheim Investigational Site
Lund, Sweden
9.159.2211 Boehringer Ingelheim Investigational Site
Mora, Sweden
9.159.2216 Boehringer Ingelheim Investigational Site
Skellefteå, Sweden
9.159.2215 Boehringer Ingelheim Investigational Site
Skövde, Sweden
9.159.2225 Boehringer Ingelheim Investigational Site
Stockholm, Sweden
9.159.2222 Boehringer Ingelheim Investigational Site
Stockholm, Sweden
9.159.2212 Boehringer Ingelheim Investigational Site
Stockholm, Sweden
9.159.2213 Boehringer Ingelheim Investigational Site
Stockholm, Sweden
9.159.2203 Boehringer Ingelheim Investigational Site
Stockholm, Sweden
9.159.2207 Boehringer Ingelheim Investigational Site
Umeå, Sweden
9.159.2214 Boehringer Ingelheim Investigational Site
Värnamo, Sweden
9.159.2224 Boehringer Ingelheim Investigational Site
Västervik, Sweden
9.159.2208 Boehringer Ingelheim Investigational Site
Örebro, Sweden
Taiwan
9.159.2250 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
9.159.2253 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
9.159.2249 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
9.159.2248 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
9.159.2251 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
9.159.2244 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
9.159.2245 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
9.159.2246 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
9.159.2247 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
9.159.2252 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
9.159.2254 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
9.159.2243 Boehringer Ingelheim Investigational Site
Taoyuan, Taiwan
Thailand
9.159.2798 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
9.159.2800 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
9.159.2799 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
9.159.2797 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
9.159.2801 Boehringer Ingelheim Investigational Site
Chiang Mai, Thailand
Turkey
9.159.2830 Boehringer Ingelheim Investigational Site
Ankara, Turkey
9.159.2829 Boehringer Ingelheim Investigational Site
Antalya, Turkey
9.159.2831 Boehringer Ingelheim Investigational Site
Bursa, Turkey
9.159.2827 Boehringer Ingelheim Investigational Site
Eskisehir, Turkey
9.159.2826 Boehringer Ingelheim Investigational Site
Istanbul, Turkey
9.159.2825 Boehringer Ingelheim Investigational Site
Istanbul, Turkey
9.159.2828 Dkuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D.
Izmir, Turkey
Ukraine
9.159.2387 Boehringer Ingelheim Investigational Site
Dnepropetrovsk, Ukraine
9.159.2392 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
9.159.2386 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
9.159.2384 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
9.159.2385 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
9.159.2379 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
9.159.2382 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
9.159.2380 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
9.159.2390 Boehringer Ingelheim Investigational Site
Odesa, Ukraine
9.159.2389 Boehringer Ingelheim Investigational Site
Odesa, Ukraine
9.159.2391 Boehringer Ingelheim Investigational Site
Vinnytzya, Ukraine
9.159.2388 Boehringer Ingelheim Investigational Site
Zaporizhzhya, Ukraine
United Kingdom
9.159.2304 Boehringer Ingelheim Investigational Site
Belfast, United Kingdom
9.159.2297 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
9.159.2299 Boehringer Ingelheim Investigational Site
Bournemouth, United Kingdom
9.159.2301 Boehringer Ingelheim Investigational Site
Bristol, United Kingdom
9.159.2298 Boehringer Ingelheim Investigational Site
Dundee, United Kingdom
9.159.2307 Boehringer Ingelheim Investigational Site
Exeter, United Kingdom
9.159.2300 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
9.159.2296 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
9.159.2287 Boehringer Ingelheim Investigational Site
Harrow, United Kingdom
9.159.2303 Boehringer Ingelheim Investigational Site
Henshingham, Whitehaven, United Kingdom
9.159.2308 Boehringer Ingelheim Investigational Site
Leicester, United Kingdom
9.159.2295 Boehringer Ingelheim Investigational Site
Liverpool, United Kingdom
9.159.2286 Boehringer Ingelheim Investigational Site
London, United Kingdom
9.159.2293 Boehringer Ingelheim Investigational Site
London, United Kingdom
9.159.2294 Boehringer Ingelheim Investigational Site
London, United Kingdom
9.159.2305 Boehringer Ingelheim Investigational Site
Mansfield, United Kingdom
9.159.2290 Boehringer Ingelheim Investigational Site
Newcastle Upon Tyne, United Kingdom
9.159.2288 Boehringer Ingelheim Investigational Site
North Shields, United Kingdom
9.159.2285 Boehringer Ingelheim Investigational Site
Northampton, United Kingdom
9.159.2284 Boehringer Ingelheim Investigational Site
Nottingham, United Kingdom
9.159.2283 Boehringer Ingelheim Investigational Site
Poole, United Kingdom
9.159.2302 Boehringer Ingelheim Investigational Site
Rotherham, United Kingdom
9.159.2292 Boehringer Ingelheim Investigational Site
Sheffield, United Kingdom
9.159.2289 Boehringer Ingelheim Investigational Site
Southampton, United Kingdom
9.159.2306 Boehringer Ingelheim Investigational Site
Stoke on Trent, United Kingdom
9.159.2291 Boehringer Ingelheim Investigational Site
Sunderland, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
GlaxoSmithKline
Bayer
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 Oct;7(10):875-84. Epub 2008 Aug 29.

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00153062     History of Changes
Other Study ID Numbers: 9.159
Study First Received: September 9, 2005
Results First Received: February 6, 2009
Last Updated: April 22, 2014
Health Authority: Argentina: Ministry of Health
Australia: Dept of Health and Ageing Therapeutic Goods Admin
Austria: Agency for Health and Food Safety
Belgium: Federal Agency for Medicinal and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
China: Ministry of Health
Denmark: National Board of Health
Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Ministry of Health
Greece: Ministry of Health and Welfare
Hong Kong: Department of Health
India: Ministry of Health
Ireland: Irish Medicines Board
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: Ministry of Health
Japan: Pharmaceuticals and Medical Devices Agency
Korea: Food and Drug Administration
Malaysia: Ministry of Health
Mexico: Ministry of Health
Netherlands: Dutch Health Care Inspectorate
Norway: Norwegian Medicines Agency
Portugal: National Pharmacy and Medicines Institute
Russia: Pharmacological Committee, Ministry of Health
Singapore: Health Sciences Authority
South Africa: Department of Health
Spain: Ministry of Health
Sweden: The National Board of Health and Welfare
Taiwan: Department of Health
Thailand: Ministry of Public Health
Turkey: Ministry of Health Central Ethics Committee
Ukraine: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Cerebral Infarction
Stroke
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Vascular Diseases
Aspirin, dipyridamole drug combination
Clopidogrel
Telmisartan
Ticlopidine
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Purinergic Agents
Purinergic Antagonists
Purinergic P2 Receptor Antagonists
Purinergic P2Y Receptor Antagonists

ClinicalTrials.gov processed this record on October 23, 2014